Literature DB >> 25657056

Maintenance of HL-1 cardiomyocyte functional activity in PEGylated fibrin gels.

Laura R Geuss1, Alicia C B Allen2, Divya Ramamoorthy2, Laura J Suggs3.   

Abstract

Successful cellular cardiomyoplasty is dependent on biocompatible materials that can retain the cells in the myocardium in order to promote host tissue repair following myocardial infarction. A variety of methods have been explored for incorporating a cell-seeded matrix into the heart, the most popular options being direct application of an injectable system or surgical implantation of a patch. Fibrin-based gels are suitable for either of these approaches, as they are biocompatible and have mechanical properties that can be tailored by adjusting the initial fibrinogen concentration. We have previously demonstrated that conjugating amine-reactive homo-bifunctional polyethylene glycol (PEG) to the fibrinogen prior to crosslinking with thrombin can increase stability both in vivo and in vitro. Similarly, when mesenchymal stem cells are combined with PEGylated fibrin and injected into the myocardium, cell retention can be significantly increased and scar tissue reduced following myocardial infarction. We hypothesized that this gel system could similarly promote cardiomyocyte viability and function in vitro, and that optimizing the mechanical properties of the hydrogel would enhance contractility. In this study, we cultured HL-1 cardiomyocytes either on top of plated PEGylated fibrin (2D) or embedded in 3D gels and evaluated cardiomyocyte function by assessing the expression of cardiomyocyte specific markers, sarcomeric α-actin, and connexin 43, as well as contractile activity. We observed that the culture method can drastically affect the functional phenotype of HL-1 cardiomyocytes, and we present data suggesting the potential use of PEGylated fibrin gel layers to prepare a sheet-like construct for myocardial regeneration.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac cell therapy; cardiomyocyte; cell sheet; fibrin; hydrogel; mechanical properties; polyethylene glycol

Mesh:

Substances:

Year:  2015        PMID: 25657056     DOI: 10.1002/bit.25553

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

Review 1.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

Review 2.  Tissue Engineering Strategies for Myocardial Regeneration: Acellular Versus Cellular Scaffolds?

Authors:  Maribella Domenech; Lilliana Polo-Corrales; Jaime E Ramirez-Vick; Donald O Freytes
Journal:  Tissue Eng Part B Rev       Date:  2016-07-21       Impact factor: 6.389

3.  3D Biofabrication of a Cardiac Tissue Construct for Sustained Longevity and Function.

Authors:  Matthew Alonzo; Raven El Khoury; Naveen Nagiah; Vikram Thakur; Munmun Chattopadhyay; Binata Joddar
Journal:  ACS Appl Mater Interfaces       Date:  2022-05-09       Impact factor: 10.383

Review 4.  Hydrogels: Properties and Applications in Biomedicine.

Authors:  Tzu-Chuan Ho; Chin-Chuan Chang; Hung-Pin Chan; Tze-Wen Chung; Chih-Wen Shu; Kuo-Pin Chuang; Tsai-Hui Duh; Ming-Hui Yang; Yu-Chang Tyan
Journal:  Molecules       Date:  2022-05-02       Impact factor: 4.927

5.  Digging deeper: structural background of PEGylated fibrin gels in cell migration and lumenogenesis.

Authors:  A I Shpichka; P V Konarev; Yu M Efremov; A E Kryukova; N A Aksenova; S L Kotova; A A Frolova; N V Kosheleva; O M Zhigalina; V I Yusupov; D N Khmelenin; A Koroleva; V V Volkov; V E Asadchikov; P S Timashev
Journal:  RSC Adv       Date:  2020-01-24       Impact factor: 4.036

Review 6.  Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases.

Authors:  Xiaoshan Liao; Xushan Yang; Hong Deng; Yuting Hao; Lianzhi Mao; Rongjun Zhang; Wenzhen Liao; Miaomiao Yuan
Journal:  Front Bioeng Biotechnol       Date:  2020-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.